Targeting lymphocyte activation to treat rheumatoid arthritis. Joint, bone, spine : revue du rhumatisme [Joint Bone Spine] Journal article | | Title | Targeting lymphocyte activation to treat rheumatoid arthritis. | | Author(s) | Falgarone G, Semerano L, Rullé S, Boissier MC | | Institution | University of Paris 13, Li2P, EA4222, Bobigny, France; Avicenne Teaching Hospital (APHP), Department of rheumatology, 125, route de Stalingrad, 93 009 Bobigny, France. | | Source | Joint Bone Spine 2009 Jun 15. | | Abstract | The introduction of targeted treatments has radically changed the management of patients with rheumatoid arthritis (RA). Abatacept is among these new treatments emerging from recent insights into joint immunopathology. Abatacept blocks the interaction between antigen-presenting cells and T-cells, thereby diminishing T-cell activation and possibly improving overall cell regulation. In RA patients, abatacept is effective in decreasing the arthritis, pain, disability, fatigue, and radiological joint damage. Abatacept provides lasting remissions or low levels of disease activity and therefore constitutes a valuable addition to the current therapeutic armamentarium for RA, which is hoped to make a full remission an attainable goal in the overall population of RA patients. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19535279 |
|
|
| |
Advertise on this site.
| | |
|
